Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias

    ... myelodysplastic syndromes (MDS) ...

    Research Article last updated 03/05/2013 - 9:00am.

  2. Prevalence, clinical characteristics and prognosis of GATA2-related myelodysplastic syndromes (MDS) in children and adolescents

    ... and adolescents with primary myelodysplastic syndrome (MDS) and 82 cases with secondary MDS enrolled in two consecutive prospective studies of the ...

    Research Article last updated 04/29/2016 - 10:24am.

  3. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry

    ... BACKGROUND: Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal stem cell disorders characterized by ... 40% of patients. Transfusion-dependent patients develop secondary iron overload . The influence of serum ferritin (SF) ...

    Research Article last updated 10/06/2016 - 1:01pm.

  4. What is Secondary MDS? Everything You Need to Know

    ... Treatment-related MDS, also known as secondary MDS , makes up a small fraction of cases of MDS. It is most ...

    LMS Item last updated 06/10/2016 - 1:24pm.

  5. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents

    ... of RBC transfusion independence (TI) ≥ 8 weeks. Secondary end points were RBC-TI ≥ 24 weeks, duration of RBC-TI, erythroid ... myelodysplastic syndromes (MDS) ...

    Research Article last updated 07/18/2016 - 10:30am.

  6. Recurrent and Secondary MDS

    Is MDS that returns after treatment(s) have successfully controlled it considered ... What is the difference between de novo MDS and secondary MDS ? De novo MDS refers to an MDS that has arisen without an obvious or specifi c cause. Secondary MDS tend to have two general categories: the first is MDS that seem ...

    Interview last updated 10/24/2012 - 1:12pm.

  7. What is Secondary MDS? Everything You Need to Know

    ... Treatment-related MDS, also known as secondary MDS , makes up a small fraction of cases of MDS. It is ...

    LMS Item last updated 06/10/2016 - 1:24pm.

  8. Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and po

    ... and intermediate-1-risk) myelodysplastic syndromes (MDS) with poor prognostic features including anemia and/or ... according to International Working Group 2006 criteria. Secondary endpoints include overall survival, hematologic response including ...

    Research Article last updated 06/23/2016 - 10:17am.

  9. Pediatric myelodysplastic syndromes: they do exist!

    ... malignancies in adults, myelodysplastic syndrome (MDS) is a heterogenous group of clonal disorders characterized by peripheral ... in ≥1 blood cell lineages. MDS frequently evolves to secondary acute myeloid leukemia with poor prognosis. Although uncommon among ...

    Research Article last updated 01/08/2014 - 9:02am.

  10. Eltrombopag Added to IST Yields Encouraging Results

    ... of eltrombopag may impact the risk of clonal evolution to MDS. A small portion (10-20%) of patients with aplastic anemia can develop MDS ... data following transplant. How important are the stated secondary outcomes: overall survival, overall response, relapse, and clonal ...

    Interview last updated 05/24/2017 - 7:44am.